Bladder virus therapy for high-risk non-muscle invasive cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of virus therapy that is put directly into the bladder for people with high-risk bladder cancer that hasn't spread into the muscle. The goal is to see if it is safe and effective at keeping the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk non-muscle invasive bladder cancer (the type that grows in the lining but hasn't reached muscle).
- All visible tumor was removed during a recent bladder scope or surgery, or only flat cancer cells (CIS) remain.
- You are 18 or older and your overall health is fairly good (ECOG score 0-2).
- Your blood counts, liver, kidney, and heart function are within normal limits. Volunteers must have adequate organ function.
- You cannot have had prior radiation to the bladder, certain previous treatments (like BCG within 2 weeks), other active cancers, or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This study tests a new drug called UGN-501, given directly into the bladder through a catheter, for people whose bladder cancer (non-muscle invasive) has returned after previous treatments. It aims to find the right dose and see if it helps control the cancer.
This trial tests a combination of targeted therapy (Disitamab Vedotin), immunotherapy (PD-1 inhibitor), and radiation to help avoid bladder removal. It is for people with HER2-high muscle-invasive bladder cancer who have had a maximal transurethral resection (TURBT).
This trial tests an “oncolytic virus” treatment given into the bladder to fight high-grade non–muscle-invasive bladder cancer. It may help people whose bladder cancer did not respond to initial bladder prevention treatments, potentially delaying or avoiding major bladder surgery.
This study tests a new drug called VT-101 for people with a type of bladder cancer that hasn't spread into the muscle wall. The goal is to see if the drug is safe and effective. It might be an option if you have already had a biopsy and are not eligible for or refuse surgery.
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.